Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study in Healthy Volunteers to Evaluate the Therapeutic Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Human Challenge Model
Phase of Trial: Phase II
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Diridavumab (Primary)
- Indications Influenza A virus H1N1 subtype; Influenza A virus infections
- Focus Therapeutic Use
- 07 Mar 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2018.
- 20 Dec 2017 Planned End Date changed from 1 Dec 2018 to 1 Jun 2018.
- 20 Dec 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2018.